T cell receptor recognizing peptide–HLA complex (TCR (when context is clear; otherwise specify with "pMHC" or "peptide-HLA" as in TCR–pMHC complex))

The **T cell receptor recognizing peptide–HLA complex** refers to the molecular complex formed when a clonotypic, heterodimeric T cell receptor (often an α/β TCR) expressed on T lymphocytes binds to a specific peptide antigen that is presented by a major histocompatibility complex (MHC), called HLA in humans, on the surface of an antigen-presenting cell[1][2][4][7]. TCR recognition of the peptide–HLA (pMHC) complex is the fundamental event that initiates cellular adaptive immune responses, driving T cell activation, cytokine production, and target cell killing[3][5][6][7]. The specificity of this interaction underlies vaccine responses, immune surveillance of infections and tumors, transplant rejection, and the pathogenesis of autoimmune diseases. The TCR–pMHC axis is central to many next-generation immunotherapies, including engineered TCR therapies and bispecifics, but therapeutic targeting is challenged by the need for exquisite specificity to avoid dangerous cross-reactivity[7].

Other names

TCR–pMHC complexT cell receptor–peptide–MHC complexT cell receptor–peptide–HLA complexT cell antigen receptor complexTCR–CD3–peptide–MHC complex

Binding to peptide–MHC complex to elicit T cell signaling and cytotoxicity (in therapeutic TCRs) Bridging cancer antigen–presenting cells to cytotoxic T cells (bispecifics, ImmTACs) Modulation/blockade of TCR signaling (antagonists, checkpoint inhibitors) Engineering TCR specificity for redirected T cell responses (cell therapies)